Home Supplements That Start With I Inositol hexaniacotinate: Circulation Support for Raynaud’s and Claudication, Evidence, Dosage, and Risks

Inositol hexaniacotinate: Circulation Support for Raynaud’s and Claudication, Evidence, Dosage, and Risks

October 6, 2025 Modified date: October 6, 2025

Inositol hexaniacotinate—often labeled as inositol hexanicotinate, inositol nicotinate, or simply “no-flush niacin”—is a compound that links six molecules of nicotinic acid (niacin) to one molecule of myo-inositol. It was created to deliver niacin gradually, reducing the warm, red flushing that many people find uncomfortable with immediate-release niacin. You will see it promoted for circulation (cold hands, intermittent claudication, Raynaud’s phenomenon), cholesterol support, and general “vascular health.” Yet it does not behave identically to plain niacin, and its benefits are not interchangeable with modern, evidence-based therapies for cardiovascular risk. This guide explains what inositol hexaniacotinate (IHN) is, how it works, where the evidence stands, how to use it thoughtfully if you choose to try it, and—equally important—who should avoid it.

Essential Insights

May reduce flushing versus immediate-release niacin and has mixed, mostly older evidence for Raynaud’s symptoms or walking discomfort from poor circulation.
High doses can still cause problems (liver strain, glucose changes, gout flare); medication interactions are possible.
Typical supplement range: 250–1,000 mg per serving; clinical studies used 2,000–4,000 mg/day in divided doses under medical supervision.
Avoid self-directed use if you have active liver disease, significant gout, uncontrolled diabetes, peptic ulcer, are pregnant or breastfeeding, or take anticoagulants.

What is inositol hexaniacotinate and how does it work?
Does it help circulation problems in real life?
What about cholesterol and other claimed benefits?
How to take it: forms, dosage, timing, and practical tips
Safety, side effects, interactions, and who should avoid it
Evidence: what strong studies and guidelines actually show

What is inositol hexaniacotinate and how does it work?

Inositol hexaniacotinate (IHN) is an ester of niacin and inositol: one inositol “core” holds six nicotinic acid molecules. This structure changes how niacin appears in the bloodstream. With immediate-release nicotinic acid, you get a rapid rise in free niacin—hence the classic flush (warmth, redness, tingling). With IHN, enzymatic hydrolysis gradually cleaves niacin off the inositol backbone so the release is slower and peak levels are lower. The reduced spike is why many users notice less or no flushing.

That slower appearance has trade-offs. First, bioavailability of free niacin from IHN is lower and more variable than from nicotinic acid or nicotinamide. In practice, a milligram of IHN doesn’t deliver the same “active” niacin exposure as a milligram of plain nicotinic acid. Second, effects tied to high free-niacin peaks (like strong lipid changes) are blunted with IHN unless very large, divided doses are used—and even then, exposure can be inconsistent.

Mechanistically, any clinical effects from IHN stem from nicotinic acid ultimately binding to niacin receptors on adipocytes, immune cells, and vascular tissue, as well as downstream changes in lipid metabolism and vasodilation mediated by prostaglandins. Because IHN releases nicotinic acid slowly, vasodilation is milder and less likely to trigger intense flushing. The inositol portion serves chiefly as the carrier; at typical IHN doses, inositol’s independent effects are minimal compared with dedicated myo-inositol supplements.

Where is IHN used? Historically, it has been tried for peripheral circulation complaints—intermittent claudication due to peripheral artery disease (PAD) and Raynaud’s phenomenon. Much of the clinical literature is decades old, with modest sample sizes and mixed results. Contemporary vascular care emphasizes supervised exercise therapy, smoking cessation, and, when medication is needed, agents with stronger evidence for symptom relief. That doesn’t make IHN useless; it places it in a role as a possible adjunct or alternative when first-line strategies are not tolerated and when a clinician is monitoring response and safety.

Key point: IHN is not “niacin without side effects.” It is a slower, lower-exposure delivery form that usually reduces flushing but also reduces the intensity of niacin’s pharmacologic effects. Use it—if at all—for carefully selected goals, not as a drop-in replacement for proven cardiovascular therapies.

Does it help circulation problems in real life?

Two real-world scenarios drive most questions about IHN: walking-related leg pain from PAD (intermittent claudication) and cold-triggered finger symptoms in Raynaud’s phenomenon.

Intermittent claudication (PAD). Older controlled trials of IHN in PAD reported conflicting outcomes. Some small studies showed increases in pain-free walking distance or symptom relief; others found little difference versus placebo over several months. Differences in dose (often 2–4 g/day divided), patient selection, and outcome measures likely contributed to the inconsistency. Today, guideline committees focus on therapies with clearer, reproducible benefits: supervised exercise programs, smoking cessation, and aggressive management of blood pressure, lipids, and diabetes. When a medication is indicated for lifestyle-limiting claudication, specific vasodilatory or antiplatelet agents with more consistent evidence are typically preferred, depending on region and patient profile. In that landscape, routine IHN use for claudication is uncommon.

Raynaud’s phenomenon. Here, older controlled trials and observational reports are somewhat more encouraging, though still limited. Multi-gram daily dosing over cold seasons has been associated with reductions in attack frequency and severity for some patients. Responses vary, and not all endpoints consistently favored IHN. Because first-line management of Raynaud’s starts with non-pharmacologic strategies (thermal protection, trigger reduction) and often a calcium channel blocker when medication is needed, IHN sits as a potential second-line adjunct when standard approaches are insufficient or not tolerated. If tried, clinicians often use a time-limited trial (8–12 weeks) and continue only if patients report a meaningful change in attacks or finger discomfort.

Setting expectations and measuring outcomes. If you and your clinician elect to test IHN for circulation symptoms, define success up front. Example goals include a 15–25% increase in pain-free walking distance or a clear reduction in weekly Raynaud’s attacks. Track these measures for 8–12 weeks at a steady dose. If the goal is not met, discontinue and pivot to other strategies. Importantly, IHN should never be used as a substitute for PAD “foundation” care such as supervised exercise, smoking cessation, foot protection, and guideline-directed medical therapy.

Bottom line. IHN can help some individuals with cold-induced finger symptoms or modest walking discomfort, but its evidence base is older and inconsistent compared with current standards. Consider it—if at all—after foundational measures, with a defined trial window and clinician oversight.

What about cholesterol and other claimed benefits?

Classic niacin (immediate-release nicotinic acid) can raise HDL-C and lower LDL-C and triglycerides at pharmacologic totals of 1,000–3,000 mg/day. However, large modern outcome trials showed that adding prescription niacin to statins did not reduce cardiovascular events and did increase adverse effects. Those results changed practice: clinicians rarely prescribe niacin for event reduction today, and even less so in the “flush-reduced” formulations.

IHN complicates the picture further. Because it releases nicotinic acid slowly and yields lower peaks, the lipid-changing power of IHN at typical supplement doses is modest. Small, older studies saw limited lipid effects with multi-gram daily dosing over months, but the evidence is not robust enough to recommend IHN for cholesterol management—particularly when contemporary, outcome-proven options exist (high-intensity statins, ezetimibe, PCSK9-targeted therapies).

Other promoted benefits appear in marketing materials, but the data are either preliminary or not specific to IHN:

Microcirculation support: Physiologic plausibility (gradual vasodilation), with decades-old data in niche indications; modern, large trials are lacking.
Neuropathic discomfort: Evidence is anecdotal; mechanistic links are weak.
Glycemic effects: At high exposures, niacin can worsen insulin resistance. IHN likely has a lower risk at modest doses, but glucose monitoring is sensible in people with diabetes or prediabetes.
General “vascular health”: Too broad to evaluate; for true cardiovascular risk reduction, use guideline-supported therapies first.

If your main goal is to improve cardiovascular outcomes, proven strategies should take priority: statins when indicated, blood pressure control, smoking cessation, exercise, and dietary patterns with strong evidence. IHN is not a substitute for these. If your personal goal is symptom relief in Raynaud’s or mild claudication, a supervised, time-boxed IHN trial can be reasonable after first-line options.

How to take it: forms, dosage, timing, and practical tips

Forms and labeling. You will see “inositol hexanicotinate,” “inositol hexaniacinate,” “inositol nicotinate,” or “no-flush niacin.” Capsule strengths commonly range from 250–500 mg; some products offer 1,000 mg. Labels may also report “niacin” content; keep in mind that milligrams of IHN are not equivalent to milligrams of immediate-release nicotinic acid in terms of delivered exposure.

How supplement doses compare with study doses.

Many circulation studies used 2,000–4,000 mg/day of IHN in divided doses for weeks to months—with medical supervision and safety monitoring.
Over-the-counter use often involves 250–1,000 mg once or twice daily, which is typically better tolerated but may not reproduce effects from higher-dose trials.

Practical dosing templates (informational, not medical advice):

Conservative trial: 250–500 mg with food once daily for 3–5 days, then 500 mg twice daily if tolerated. Reassess at 8–12 weeks.
Clinician-supervised circulation trial: 500–1,000 mg with meals, 2–4 times daily, titrated over 1–2 weeks, with lab checks as appropriate. Stop if no clear benefit by 12 weeks.
Do not combine IHN with prescription niacin or other high-dose B3 products unless your clinician explicitly directs you to do so.

Timing and food. Taking IHN with meals generally reduces any residual flushing or queasiness. Split dosing (morning/evening or 3–4 times daily) is common when totals exceed 1,000 mg/day.

Quality signals. Favor brands that disclose the exact chemical form (inositol hexanicotinate), strength per capsule, lot number, and third-party testing (USP, NSF, or comparable). Avoid products that vaguely list “inositol niacinate complex” without milligram amounts.

When to expect a result. If IHN is going to help with Raynaud’s or walking discomfort, many responders notice a difference within 4–8 weeks after reaching a stable dose. Absence of benefit by 12 weeks is a reasonable stop point.

When to stop immediately. Stop and seek medical advice if you develop persistent nausea, abdominal pain, unexplained fatigue, dark urine, yellowing of the eyes/skin, severe itching, worsening gout, or new muscle pain (especially if taking a statin).

Special groups. Pregnant or breastfeeding individuals, adolescents, and people with chronic liver disease, peptic ulcer, significant gout, or poorly controlled diabetes should not start IHN without clinician guidance. In these groups, the risk-benefit balance can differ dramatically.

Storage and stability. Keep capsules dry, away from heat and light. Discard products past expiration or if odor/color changes occur.

Safety, side effects, interactions, and who should avoid it

Tolerability profile. Compared with immediate-release niacin, IHN is less likely to trigger intense flushing. Still, some people feel mild warmth, tingling, or facial redness—especially during dose increases. Gastrointestinal symptoms (fullness, queasiness, loose stools) can occur at higher totals or on an empty stomach.

Liver health. High-dose niacin has been linked to elevated liver enzymes and, rarely, serious hepatotoxicity; sustained-release forms carry particular risk at multi-gram intakes. IHN appears to pose lower liver risk at typical supplement doses, but the risk is not zero—especially with multi-gram regimens, alcohol use, or other hepatotoxic drugs. Anyone using high doses should discuss baseline and periodic liver enzyme checks with a clinician.

Metabolic effects. Niacin exposure can worsen glycemic control in some individuals. With IHN, that risk seems lower at modest doses but rises with higher totals. People with diabetes or prediabetes should monitor glucose when starting or increasing IHN.

Uric acid and gout. Niacin can raise uric acid and precipitate flares. If you have a history of gout, approach IHN cautiously and in consultation with your clinician.

Blood pressure and dizziness. Vasodilation may mildly lower blood pressure in some users. Those on antihypertensives should watch for lightheadedness on standing—particularly during titration.

Medication and supplement interactions (selected):

Anticoagulants/antiplatelets (e.g., warfarin, DOACs, clopidogrel): Report unusual bruising or bleeding; clinicians may increase monitoring.
Statins: While IHN is not usually paired with statins for lipids, any niacin exposure plus statin can raise the chance of myalgias; report unexplained muscle symptoms.
Diabetes medications: Monitor glucose more closely during IHN dose changes.
Hepatotoxic drugs or alcohol: Combined use raises liver risk; keep alcohol moderate and review medications with your clinician.
Bile acid sequestrants or other binders: Separate dosing by several hours to avoid absorption issues.

Who should avoid self-directed IHN:

Active liver disease or unexplained persistent liver enzyme elevations.
Significant gout or high uric acid that is not well controlled.
Active peptic ulcer disease.
Pregnancy or breastfeeding (insufficient safety data at supplemental doses).
Children and adolescents, unless a clinician recommends and monitors for a defined indication.
Individuals preparing for surgery or with bleeding disorders (stop well in advance and inform the surgical team).

Monitoring at higher doses (>1,500–2,000 mg/day) or longer durations (>12 weeks): Periodic liver enzymes, fasting glucose or A1C, and uric acid can be considered. Review all medications and alcohol intake. Re-assess the original goal; if it is not being met, discontinue.

Practical safety takeaways. Start low and go slow. Pair with meals. Set a clear stop date if no benefit appears. Keep your healthcare team informed—especially if you have chronic conditions or take prescription medications.

Evidence: what strong studies and guidelines actually show

Niacin outcomes in modern cardiology. Large, well-designed trials tested whether adding a prescription niacin regimen to statin therapy prevents heart attacks, strokes, or deaths. Results were negative: despite improving lab lipids, niacin did not reduce major cardiovascular events and increased certain adverse effects. These trials used extended-release nicotinic acid (sometimes combined with a flushing blocker) rather than IHN, but they directly inform today’s practice: clinicians prioritize therapies that improve outcomes, not just lab numbers. Consequently, niacin—of any form—is rarely used to reduce events in statin-treated patients.

IHN for intermittent claudication. Controlled trials from the 1980s tested multi-gram daily doses of IHN in people with PAD. Some reported improved symptoms or walking distances, others did not. Sample sizes were small, designs varied, and results were inconsistent. Modern guidelines for PAD emphasize supervised exercise therapy, smoking cessation, risk-factor control, and selective pharmacotherapy (based on local approvals and patient characteristics). Routine IHN use is not a guideline-endorsed strategy for improving walking distance.

IHN for Raynaud’s phenomenon. A small double-blind, placebo-controlled study reported fewer or less severe vasospastic episodes with 4 g/day of IHN during cold weather for primary Raynaud’s; other reports are mixed. Current first-line therapy remains lifestyle protection and, when needed, a dihydropyridine calcium channel blocker. IHN is a possible adjunct in select, refractory cases with careful monitoring.

Pharmacology and absorption. Authoritative nutrition references note that niacin derived from IHN is absorbed more slowly and, on average, to a lesser extent than nicotinic acid or nicotinamide. This explains both the lower flush rate and the lower “pharmacologic punch” at typical supplement doses.

What this means for you. If you are considering IHN, anchor the decision to a specific symptom goal (e.g., Raynaud’s attacks) rather than broad hopes like “heart health.” For cholesterol or event reduction, proven medications and lifestyle interventions outperform IHN on both efficacy and evidence quality. For PAD symptoms, exercise therapy remains the star. If you try IHN, make it a short, measured experiment with clear criteria for success and safety monitoring.

References

Disclaimer

This article is for general information only and does not replace personalized medical advice. Inositol hexaniacotinate can interact with health conditions and medications, and higher doses may require laboratory monitoring. Do not start, stop, or change any supplement or treatment without guidance from a qualified clinician who knows your medical history, medications, and goals. If you have liver disease, gout, diabetes, peptic ulcer disease, Raynaud’s phenomenon, or peripheral artery disease, consult your healthcare professional before using this supplement.

If you found this guide useful, please consider sharing it on Facebook, X (formerly Twitter), or any platform you prefer, and follow us for future evidence-based articles. Your support helps us continue producing high-quality resources.